Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics.
María Dolores Arenas JimenezEmilio González-ParraClara BarriosAbraham Rincón BelloAna López-HerradónHigini CaoSara HurtadoSilvia ColladoLaura RiberaFrancesc BarbosaFabiola DapenaVicent TorregrosaJosé Jesús BrosetaCarlos Soto MontañezJuan Francisco Navarro-GonzálezRosa RamosJordi BoverXavier Nogués-SolanMarta CrespoAdriana S DussoJulio PascualPublished in: Nutrients (2021)
Our findings suggest that the use of paricalcitol, calcimimetics or the combination of both, seem to be associated with the improvement of survival in HD patients with COVID-19. No correlation was found between serum VD levels and prognosis or outcomes in HD patients with COVID-19. Prospective studies and clinical trials are needed to support these findings.